diaDexus PLAC test for heart disease
This article was originally published in The Gray Sheet
Executive Summary
Adjunctive, predictive laboratory test for congestive heart disease receives 510(k) clearance July 18. The blood test measures the level of the enzyme lipoprotein-associated phospholipase A2, which is created by macrophages when a person has CHD, FDA explains. "An elevated PLAC test result with an LDL-cholesterol level of less than 130 mg/dL gives doctors increased confidence that patients have two-to-three times the risk of having [CHD] when compared with patients having lower PLAC test results," according to the agency. The test was developed by San Francisco-based diaDexus and GlaxoSmithKline (1"The Gray Sheet" June 10, 2002, p. 8)...
You may also be interested in...
Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.